Clinical TrialMay 4, 2026, 09:11 AM
Oncolytics Biotech Reports 19.5-Month Response in Colorectal Cancer Study
AI Summary
Oncolytics Biotech Inc. announced new durability data from its REO 022 study in metastatic colorectal cancer, demonstrating a 19.5-month median duration of response in second-line KRAS-mutant MSS mCRC patients. This represents a significant 3-4x improvement over historical benchmarks. The pelareorep-based combination therapy also achieved a 33% objective response rate, tripling the standard of care. The company is actively engaging with the FDA to discuss a potential accelerated approval pathway based on these compelling results.
Key Highlights
- Pelareorep-based combination therapy achieved a 19.5-month median duration of response in 2L KRAS-mutant MSS mCRC.
- This duration of response represents a 3-4x improvement over historical benchmarks of 4-6 months.
- The objective response rate for the pelareorep combination was 33%.
- This 33% objective response rate triples the 6-11% seen with standard of care.
- Oncolytics Biotech is engaging with the FDA to discuss a potential accelerated approval pathway.
- The company is currently enrolling patients in a randomized Phase 2 study for the same indication.